|
| Press Releases |
|
 |
|
| Saturday, August 31, 2013 |
|
|
NANOBIOTIX: Half Year Results for the Period Ended 30 June 2013 |
| NANOBIOTIX (the "Company") (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has published today its half year results for the six month period ended 30 June 2013 (HY1). more info >> |
|
| Thursday, July 4, 2013 |
|
|
Nanobiotix Announces EUR 2.8 Million Grant from bpifrance to Accelerate Development of NBTXR3 in a Third New Indication |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today it has secured c.EUR 9 million in funding from bpifrance (formerly OSEO) of which EUR 2.8 million is directly attributable to the Company. more info >> |
|
| Wednesday, June 26, 2013 |
|
|
Nanobiotix Announces the Selection of its Second NanoXray Product, NBTX-IV and a Collaboration with the National Cancer Institute for Development |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces the selection of a new product for development, NBTX-IV. more info >> |
|
| Thursday, June 13, 2013 |
|
|
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO) announces today that its lead compound NBTXR3 has received authorization from the French Medicine Agency, ANSM, to start a clinical trial in patients with locally advanced cancers of the oral cavity or oropharynx (head and neck cancer), at the Institut Curie, Paris, France, a French leading cancer treatment center. more info >> |
|
| Monday, June 3, 2013 |
|
|
Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive Phase I interim results of its lead nanoparticle-based product, NBTXR3, in patients with Soft Tissue Sarcoma (STS). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
JDE Peet's 正式启用 OMP 的 Unison Planning(TM) 系统，大规模提升供应链价值
Apr 1, 2026 21:50 HKT/SGT
|
|
|
JDE Peet's Goes Live with OMP's Unison Planning(TM), Accelerating Supply Chain Value at Scale
Apr 1, 2026 21:50 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 21:00: JST
|
|
|
GMG Verified by Advanced Carbons Council & Successful ISO9001 Audit
Apr 1, 2026 21:00 HKT/SGT
|
|
|
Datavault AI 再度現身馬阿拉戈，出席專屬投資者論壇
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI 再度亮相马阿拉戈，参加独家投资者论坛
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago
Apr 1, 2026 20:00 HKT/SGT
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 19:52: JST
|
|
|
Four leading spring tech fairs will take place in April, featuring over 3,700 exhibitors
Apr 1, 2026 18:52 HKT/SGT
|
|
|
True IDC Pushes "Security Economy", Breaking Ground on Mega Data Center in EEC with 77-Billion-Baht BOI Investment, Cementing Thailand's No. 1 Position
Apr 1, 2026 18:50 HKT/SGT
|
|
|
China Risun (01907.HK) Reports Strong 37.7% Net Profit Surge in 2025 Amid Industry Challenges
Apr 1, 2026 18:07 HKT/SGT
|
|
|
中國旭陽集團（01907.HK）積極面對行業變化 2025年淨利逆勢增長37.7%
Apr 1, 2026 17:50 HKT/SGT
|
|
|
中国旭阳集团（01907.HK）积极面对行业变化 2025年净利逆势增长37.7%
Apr 1, 2026 17:42 HKT/SGT
|
|
|
CTF Life Collaborates with the HKMC to Refer the Policy Reverse Mortgage Programme and the Reverse Mortgage Programme
Apr 1, 2026 16:20 HKT/SGT
|
|
|
周大福人壽與香港按揭證券有限公司合作
Apr 1, 2026 16:02 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
